最新ニュース 10x Genomics (NASDAQ:TXG) 株価情報

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

WWE has reportedly removed <a href="https://www.benzinga.com/cannabis">marijuana</a> from its list of banned substances, according to <a href="https://www.youtube.com/watch?v=4z2VXh-cw_o">recent statements</a> by WWE superstar Michin aka Mia Yim. While WWE has yet to issue an official confirmation, Michin disclosed this policy change during an <a href="https://www.postwrestling.com/2025/02/17/michin-confirms-wwe-took-marijuana-off-their-banned-substances-list/">appearance</a> earlier this month on &#8220;The Speakeezy&#8221; podcast, highlighting a shift in the company&#8217;s stance toward cannabis use among its talent.
<h3 class="wp-block-heading">Major Policy Shift, But No Official Confirmation</h3>
Speaking on the podcast, Michin explained that WWE quietly eliminated marijuana from its list of banned substances &#8220;a couple years ago.&#8221; She stated, &#8220;Because it's [marijuana] more legal, they've kind of accepted it. So before, that used to be — marijuana used to be on the drug list and they took that off a couple years ago.&#8221;
Benzinga contacted WWE twice seeking confirmation of Michin&#8217;s comments but has not received a response at the time of publication. 
Also read: <a href="https://www.benzinga.com/general/sports/25/02/43790624/brittney-griner-cancels-cannabis-keynote-after-finding-disturbing-hotel-room-message">Brittney Griner Cancels Cannabis Keynote After Finding Disturbing Hotel Room Message</a>
The wrestler&#8217;s comments suggest that WWE performers are no longer penalized for marijuana use, a notable departure from previous policies that imposed fines on talent who tested positive for the substance. WWE has not publicly confirmed or commented on Michin&#8217;s remarks. 
<h3 class="wp-block-heading">WWE&#8217;s Past Stance On Marijuana Use</h3>
For decades, WWE maintained a strict wellness policy that categorized marijuana as a banned substance. Wrestlers caught using cannabis often faced fines, with notable names such as Randy Orton and Jack Swagger <a href="https://www.thesportster.com/wrestling/pro-wrestlers-who-smoked-weed-marijuana/">among those penalized</a> for testing positive. This hardline approach was part of WWE's broader drug policy, enacted in response to public scrutiny and past controversies related to substance abuse within the industry.
As marijuana laws have evolved across the United States, WWE's stance has appeared to soften. While fines for cannabis use reportedly continued into the early 2020s, Michin's comments indicate the company may have fully allowed marijuana use by its talent.
<h3 class="wp-block-heading">Growing Trend In Sports, Entertainment</h3>
If Michin's comments hold true, WWE would be joining a broader trend in professional sports. Major organizations, <a href="https://www.benzinga.com/markets/cannabis/23/12/36436093/ufc-knocks-out-marijuana-ban-major-shift-in-professional-athlete-drug-policy">including the UFC</a>, have already revised drug policies to remove marijuana from banned substance lists. The shift reflects both changing societal attitudes and growing recognition of cannabis's potential therapeutic benefits, particularly in managing pain and stress — two major factors affecting professional wrestlers.
In the United States, 24 states and the District of Columbia have legalized marijuana for recreational use, with an even greater number allowing medical use. WWE's policy adjustment, if confirmed, would align with these legal and cultural developments, as well as with the practices of its sister company, UFC, under the TKO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>) umbrella.
<h3 class="wp-block-heading">The Need For Official Clarification</h3>
Despite multiple reports citing Michin's remarks, WWE has not publicly acknowledged the change. Until an official statement is made, the exact details remain unclear, including whether there are still restrictions regarding in-ring performance, travel or other professional obligations.
For now, wrestlers appear to have more freedom regarding cannabis use, at least based on Michin's account. As WWE continues evolving under new leadership and its growing corporate structure, further updates on its wellness policy could be forthcoming.
Read next: <a href="https://www.benzinga.com/general/health-care/25/02/43759695/super-bowl-champs-fight-for-cannabis-opioids-are-killing-athletes">Super Bowl Champ&#8217;s Fight for Cannabis: &#8216;Opioids Are Killing Athletes&#8217;</a>
Photo: Shutterstock.

Cannabis

Sports

Media

WWE Reportedly Removes Marijuana From Banned Substances List

WIIM

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of health insurers are trading lower. Weakness in the sector may be in sympathy with UnitedHealth, which fell on reports of a DOJ investigation into Medicare billing practices.

NICE's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NYSE">NICE</a>) short percent of float has risen 21.41% since its last report. The company recently reported that it has 2.71 million shares sold short, which is 4.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.86 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>NICE Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740163526_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for NICE has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing NICE's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, NICE's peer group average for short interest as a percentage of float is 5.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

NICE

What's Driving the Market Sentiment Around NICE?

NuScale Power's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) short percent of float has risen 17.35% since its last report. The company recently reported that it has 21.61 million shares sold short, which is 18.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.39 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>NuScale Power Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740163521_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for NuScale Power has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing NuScale Power's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, NuScale Power's peer group average for short interest as a percentage of float is 11.41%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About NuScale Power?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Ranjan Sharma upgraded the rating for Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) from Neutral to Overweight and announced a $5.6 price target. Grab shares closed at $4.7850 on Thursday. <a href="https://www.benzinga.com/quote/GRAB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Eric Luebchow upgraded Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) from Underweight to Equal-Weight and announced a $5 price target. Lumen Technologies shares closed at $4.69 on Thursday. <a href="https://www.benzinga.com/quote/LUMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Caitlin Burrows upgraded First Industrial Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FR#NYSE">FR</a>) from Sell to Neutral and raised the price target from $52 to $59. First Industrial Realty shares closed at $55.77 on Thursday. <a href="https://www.benzinga.com/quote/FR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst Mike Hickey upgraded Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) from Sell to Hold. Unity Software shares closed at $28.00 on Thursday. <a href="https://www.benzinga.com/quote/U/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street analyst Mark Smith upgraded Kura Sushi USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) from Hold to Buy and maintained the price target of $103. Kura Sushi USA shares closed at $74.04 on Thursday. <a href="https://www.benzinga.com/quote/KRUS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying U stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="603" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21134408/image-180-1024x603.png" alt="" class="wp-image-793668" style="width:460px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21134408/image-180-1024x603.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21134408/image-180-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21134408/image-180-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21134408/image-180.png 1087w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43864993/top-3-health-care-stocks-you-may-want-to-dump-in-february">Top 3 Health Care Stocks You May Want To Dump In February</a></li>
</ul>

News

Upgrades

Markets

Analyst Ratings

GRAB

KRUS

LUMN

This Unity Software Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

Unity Software's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) short percent of float has risen 7.12% since its last report. The company recently reported that it has 24.47 million shares sold short, which is 6.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Unity Software Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740163515_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Unity Software has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Unity Software's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Unity Software's peer group average for short interest as a percentage of float is 5.29%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is the Market Bullish or Bearish on Unity Software?

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/02/2025-02-21_08h00_31.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">King Nvidia Earnings Ahead</h4>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-money-flow-chinese-stocks-nvidia-earnings-ahead-baba-mc-02212025">click here</a> for an enlarged chart of Chinese e-commerce company Alibaba Group Holding Ltd &#8211; ADR (BABA).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of BABA stock is being used to illustrate the point.</li>
<li>The chart shows the rise in BABA stock over the last several weeks. The rise is due to money flowing into Chinese stocks, especially BABA.</li>
<li>The chart shows when an Arora buy signal was triggered.</li>
<li>The chart shows the jump up in BABA stock yesterday on earnings.</li>
<li>The chart shows the jump up was on heavy volume, indicating conviction.</li>
<li>The chart shows the Arora signals to take partial profits during the rise and on yesterday's jump up.</li>
<li>RSI on the chart shows BABA stock is overbought.&nbsp; Overbought stocks are susceptible to a pullback.</li>
<li>Part of the buying in BABA is coming from the meme crowd after a report that Ryan Cohen, founder of Chewy Inc (CHWY), has bought almost $1B worth of BABA stock.  Previously, Ryan Cohen triggered a meme crowd buying frenzy in GameStop Corp (GME).</li>
<li>Money is flowing in aggressively in all Chinese stocks, especially tech stocks.&nbsp; Overnight, stocks in Hong Kong jumped 4%.</li>
<li>Recently, the momo crowd's favorite stocks took a hit.  In the early trade, the momo crowd is aggressively buying the dip in its favorite stocks, including Palantir Technologies Inc (PLTR), MicroStrategy Inc (MSTR), Robinhood Markets Inc (HOOD), Applovin Corp ( APP), Hims &amp; Hers Health Inc (HIMS), Oklo Inc (OKLO), IONQ Inc (IONQ), and Rigetti Computing Inc (RGTI).</li>
<li>Crypto company Coinbase Global Inc (COIN) is seeing aggressive buying after the SEC dropped a long running case against Coinbase.</li>
<li>The drop in the Dow Jones Industrial Average (DJIA) is due to only one stock, UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).  UNH stock is falling 11.6% as of this writing in the premarket. UNH stock is falling this morning on the news that the Department of Justice has launched an investigation.  The news is bringing down other stocks such as CVS Health Corp (CVS), Humana Inc (HUM), and Cigna Group (CI).</li>
<li>The main event ahead for the stock market is NVIDIA Corp (NVDA) earnings.  Investors will be looking for insights on the impact of DeepSeek on Nvidia.  As full disclosure, when NVDA stock fell on DeepSeek panic, The Arora Report gave a buy signal for a trade around position in ZYX Buy.  In The Arora Report analysis, Nvidia earnings will impact the entire stock market.  </li>
<li>University of Michigan consumer sentiment was released at 10am ET.  At The Arora Report, we will be very carefully scrutinizing this data after the lower guidance from Walmart Inc (WMT).  The data may be market moving.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), Microsoft Corp (MSFT), NVDA, and Tesla Inc (TSLA).
In the early trade, money flows are neutral in Apple Inc (AAPL).
In the early trade, money flows are neutral in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is seeing buying on SEC withdrawing its long running case against COIN.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Money Flowing Into Chinese Stocks, Especially Alibaba; The Main Event Ahead Is Nvidia Earnings

Owens Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) will release its fourth-quarter financial results after the <a href="https://www.benzinga.com/quote/oc/earnings">closing bell on Monday, Feb. 24</a>.
Analysts expect the Toledo, Ohio-based company to report quarterly earnings at $2.91 per share, down from $3.21 per share in the year-ago period. Owens Corning projects quarterly revenue of $2.77 billion, compared to $2.3 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Feb. 14, Owens Corning agreed to sell glass reinforcements business to Praana Group at an enterprise value of $755 million.
Owens Corning shares fell 1.2% to close at $172.10 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/oc/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Loop Capital analyst Garik Shmois maintained a Buy rating and cut the price target from $215 to $210 on Jan. 10, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Citigroup analyst Paul Lejuez maintained a Buy rating and slashed the price target from $212 to $207 on Jan. 6, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Barclays analyst Matthew Bouley upgraded the stock from Equal-Weight to Overweight and boosted the price target from $192 to $245 on Dec. 11, 2024. This analyst has an accuracy rate of 72%.</li>
<li>RBC Capital analyst Mike Dahl maintained an Outperform rating and raised the price target from $213 to $217 on Nov. 7, 2024. This analyst has an accuracy rate of 73%.</li>
<li>UBS analyst John Lovallo maintained a Buy rating and boosted the price target from $197 to $218 on Nov. 7, 2024. This analyst has an accuracy rate of 69%.</li>
</ul>
Considering buying OC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21042541/image-178-1024x570.png" alt="" class="wp-image-792715" style="width:607px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21042541/image-178-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21042541/image-178-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21042541/image-178-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21042541/image-178.png 1142w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43864993/top-3-health-care-stocks-you-may-want-to-dump-in-february">Top 3 Health Care Stocks You May Want To Dump In February</a></li>
</ul>

Long Ideas

Price Target

Owens Corning Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Rumors

AMD Said To Discuss Server Plant Sale With Taiwan Suitors For Up To $4B

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Seth Seifman initiated coverage on OSI Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) with a Neutral rating and announced a price target of $125. OSI Systems shares closed at $214.37 on Thursday. <a href="https://www.benzinga.com/quote/OSIS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Matthew Clark initiated coverage on FirstSun Capital Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSUN#NASDAQ">FSUN</a>) with an Overweight rating and announced a price target of $51. Firstsun Capital shares closed at $41.50 on Thursday. <a href="https://www.benzinga.com/quote/FSUN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM analyst Philip Shen initiated coverage on Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Buy rating and announced a price target of $350. Quanta Services shares closed at $281.16 on Wednesday. <a href="https://www.benzinga.com/quote/PWR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street initiated coverage on Owlet, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) with a Buy rating and announced a price target of $8.5. Owlet shares closed at $4.96 on Thursday. <a href="https://www.benzinga.com/quote/OWLT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group analyst Michael Diana initiated coverage on Mobile Infrastructure Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) with a Buy rating and announced a price target of $7. Mobile Infrastructure shares closed at $3.27 on Thursday. <a href="https://www.benzinga.com/quote/BEEP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PWR stock? Here&#8217;s what analysts think: 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43864993/top-3-health-care-stocks-you-may-want-to-dump-in-february">Top 3 Health Care Stocks You May Want To Dump In February</a></li>
</ul>

Initiation

Mobile Infrastructure Corporation Common Stock

BEEP

FSUN

OSIS

OWLT

This Quanta Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

GOOG

GOOGL

UBER

Uber CEO Dara Khosrowshahi Says Would Love To Have Tesla's Robotaxis On The Uber Network; Says Uber, Waymo Will Compete With Tesla In Austin

On Thursday, Guardant Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GH#NYSE">GH</a>) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the <a target="_blank" href="http://during the premarket session on last check Thursday." rel="noreferrer noopener">consensus loss of 74 cents</a>.
The cancer diagnostic company reported sales of $201.8 million, up 30% year over year, beating the consensus of $192.14 million, driven by an increase in the volume of clinical tests and biopharma tests, which grew <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43865627/guardant-health-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-2025-outl" rel="noreferrer noopener">24% and 16%, respectively</a>.
The company reported approximately 57,300 oncology clinical tests (excluding Shield) and 11,050 biopharma tests.
The increase in precision oncology revenue was also attributable to an increase in reimbursement for tests due to an increase in Medicare reimbursement for the Guardant360 LDT test to $5,000 and an increase in both Medicare Advantage and commercial payer reimbursement.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43110223/guardant-health-gains-medicare-coverage-for-colorectal-cancer-monitoring-test" rel="noreferrer noopener">Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test</a>
Guidance: Guardant Health forecasts fiscal year 2025 revenue of $850 million—$860 million, versus a consensus of $848.9 million.
Analyst Reaction:
<ul>
<li>William Blair has recently become more optimistic about Guardant. The stock's momentum could continue, especially if investors trust the company's strategy.</li>
<li>While some gains might slow ahead of Exact Sciences Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) midyear results for its blood-based colorectal cancer screening test, analyst Andrew F. Brackmann writes strong financial performance and Guardant's own data updates will support the stock. William Blair maintains <a href="https://www.benzinga.com/quote/GH/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.</li>
<li>Stifel analyst Daniel Arias maintains Guardant Health with a Buy and raises the price target from $45 to $53.</li>
<li>JP Morgan analyst Rachel Vatnsdal reaffirms Guardant Health's Overweight rating and raises the price target from $50 to $55.</li>
<li>Raymond James analyst Andrew Cooper reiterates Guardant Health with an Outperform and raises the price target from $39 to $59.</li>
<li>Goldman Sachs analyst Matthew Sykes maintains Guardant Health with a Buy and raises the price target from $49 to $56.</li>
</ul>
Price Action: GH stock is down 10.60% at $42.40 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43888128/pfizer-discontinues-hemophilia-gene-therapy-beqvez-interest-wanes" target="_blank" rel="noreferrer noopener">Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes</a></li>
</ul>

Analyst Color

Earnings

Guidance

Health Care

Movers

General

EXAS

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?

Financial giants have made a conspicuous bullish move on Ford Motor. Our analysis of options history for Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) revealed 9 unusual trades.
Delving into the details, we found 66% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $309,024, and 2 were calls, valued at $81,247.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $7.85 and $11.02 for Ford Motor, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Ford Motor's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Ford Motor's significant trades, within a strike price range of $7.85 to $11.02, over the past month.
<h3>Ford Motor 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740162645_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$0.69</td>
<td>$0.64</td>
<td>$0.64</td>
<td>$7.85</td>
<td>$105.6K</td>
<td>14.5K</td>
<td>0</td>
</tr>
<tr>
<td>F</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.17</td>
<td>$0.16</td>
<td>$0.17</td>
<td>$11.02</td>
<td>$50.8K</td>
<td>46.3K</td>
<td>3.3K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$0.47</td>
<td>$0.45</td>
<td>$0.47</td>
<td>$9.85</td>
<td>$47.0K</td>
<td>22.5K</td>
<td>1.4K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$0.55</td>
<td>$0.54</td>
<td>$0.54</td>
<td>$9.85</td>
<td>$38.9K</td>
<td>52.0K</td>
<td>771</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$2.12</td>
<td>$1.77</td>
<td>$1.86</td>
<td>$10.85</td>
<td>$30.8K</td>
<td>1.7K</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Ford Motor</h3>
Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has nearly 13% market share in the United States, about 10% share in the UK, and under 2% share in China including unconsolidated affiliates. Sales in the US made up about 68% of 2024 total company revenue. Ford has about 171,000 employees, including about 56,500 UAW employees, and is based in Dearborn, Michigan.
<h3>Present Market Standing of Ford Motor</h3>
<ul>
<li>With a trading volume of 28,669,045, the price of F is down by -0.91%, reaching $9.3.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 61 days from now.</li>
</ul>
<h3>Expert Opinions on Ford Motor</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $11.1.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Underweight rating on Ford Motor, which currently sits at a price target of $8. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Ford Motor, targeting a price of $10. 
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Ford Motor, maintaining a target price of $9. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Ford Motor, targeting a price of $15. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Ford Motor with a target price of $13. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Ford Motor options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

A Closer Look at Ford Motor's Options Market Dynamics

William Blair analyst Louie DiPalma downgrades Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) from Outperform to Market Perform.

Downgrades

LDOS

William Blair Downgrades Leidos Holdings to Market Perform

On Friday, Exelixis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) authorized repurchasing up to an additional $500 million of the company&#8217;s common stock before <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43868849/exelixis-announces-a-newly-authorized-500-million-stock-repurchase-program" rel="noreferrer noopener">December 31, 2025</a>.
Exelixis plans to complete the $500 million stock repurchase program, announced in August 2024, in the second quarter of 2025 and commence stock repurchases under the newly authorized stock repurchase program thereafter.
As of the end of fiscal year 2024, Exelixis has returned over $1.2 billion to shareholders through these programs.
Earlier this month, Exelixis reported fourth-quarter adjusted EPS of 55 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 43 cents</a>. The cancer-focused company reported sales of $566.75 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640071/exelixis-announces-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-corporate-up" rel="noreferrer noopener">consensus of $563.42 million</a>.
Exelixis reaffirmed its 2025 sales guidance of $2.15 billion-$2.25 billion versus consensus of $2.24 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42488323/drug-price-hikes-unsupported-by-evidence-cost-us-815-million-icer-report" rel="noreferrer noopener">Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report</a>
Recently, Exelixis announced the final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx&nbsp;(cabozantinib) in combination with Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo&nbsp;(nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC).
After more than five years of follow-up, the findings demonstrated that the efficacy benefits of Cabometyx&nbsp;in combination with Opdivo were sustained long-term.
At a median follow-up of 67.6 months, Cabometyx, in combination with Opdivo, improved progression-free survival and overall survival compared with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Sutent (sunitinib) in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43756537/exelixis-announces-final-five-year-follow-up-results-from-checkmate-9er-trial-evaluating-cabometyx" rel="noreferrer noopener">intent-to-treat population</a>.
A subgroup analysis by the International Metastatic RCC Database Consortium (IMDC) risk showed PFS and objective response rates favored Cabometyx in combination with Opdivo versus sunitinib regardless of the IMDC risk group.
In January, Exelixis announced that its supplemental New Drug Application (sNDA) for cabozantinib for adults with previously treated advanced pancreatic neuroendocrine and extra-pancreatic tumors will no longer be discussed at the FDA&#8217;s Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by the FDA and has a Prescription Drug User Fee Act action <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42896345/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-" rel="noreferrer noopener">date of April 3</a>.
Price Action: EXEL stock is up 3.42% at $36.29 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43888652/trump-medias-strategic-fund-set-to-fuel-mergers-and-acquisitions" target="_blank" rel="noreferrer noopener">Trump Media&#8217;s Strategic Fund Set To Fuel Mergers And Acquisitions: Details</a></li>
</ul>

Biotech

Buybacks

EXEL

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Whales with a lot of money to spend have taken a noticeably bearish stance on Cleanspark.
Looking at options history for Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) we detected 29 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 48% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $359,087 and 22, calls, for a total amount of $987,395.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $4.0 to $37.0 for Cleanspark over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cleanspark's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cleanspark's whale activity within a strike price range from $4.0 to $37.0 in the last 30 days. 
<h3>Cleanspark Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740162639_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.36</td>
<td>$1.32</td>
<td>$1.32</td>
<td>$12.00</td>
<td>$132.0K</td>
<td>6.7K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.35</td>
<td>$1.32</td>
<td>$1.32</td>
<td>$12.00</td>
<td>$98.9K</td>
<td>6.7K</td>
<td>32</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$11.00</td>
<td>$91.2K</td>
<td>89</td>
<td>37</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.72</td>
<td>$0.7</td>
<td>$0.72</td>
<td>$10.00</td>
<td>$72.0K</td>
<td>7.4K</td>
<td>6</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$1.15</td>
<td>$1.11</td>
<td>$1.12</td>
<td>$15.00</td>
<td>$67.5K</td>
<td>21.2K</td>
<td>6.2K</td>
</tr>
</tbody>
</table>

<h3>About Cleanspark</h3>
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
Having examined the options trading patterns of Cleanspark, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Cleanspark</h3>
<ul>
<li>Currently trading with a volume of 13,035,522, the CLSK's price is down by -5.67%, now at $9.49. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
<h3>What Analysts Are Saying About Cleanspark</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $24.666666666666668.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $27. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $20. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $27. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cleanspark with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

CLSK

Cleanspark Unusual Options Activity

Financial giants have made a conspicuous bearish move on Freeport-McMoRan. Our analysis of options history for Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) revealed 19 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 57% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $501,366, and 12 were calls, valued at $687,517.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $45.0 for Freeport-McMoRan over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Freeport-McMoRan stands at 4432.4, with a total volume reaching 8,242.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Freeport-McMoRan, situated within the strike price corridor from $30.0 to $45.0, throughout the last 30 days.
<h3>Freeport-McMoRan Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740162633_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$35.00</td>
<td>$155.0K</td>
<td>833</td>
<td>25</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.45</td>
<td>$7.3</td>
<td>$7.35</td>
<td>$35.00</td>
<td>$147.0K</td>
<td>813</td>
<td>2</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.31</td>
<td>$2.3</td>
<td>$2.3</td>
<td>$38.00</td>
<td>$114.7K</td>
<td>1.9K</td>
<td>3.0K</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.47</td>
<td>$1.13</td>
<td>$1.27</td>
<td>$40.00</td>
<td>$99.7K</td>
<td>8.4K</td>
<td>0</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.89</td>
<td>$1.88</td>
<td>$1.88</td>
<td>$39.00</td>
<td>$93.8K</td>
<td>1.5K</td>
<td>564</td>
</tr>
</tbody>
</table>

<h3>About Freeport-McMoRan</h3>
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2024, making it the one of the world's largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. It had about 25 years of copper reserves at end December 2024. we expect it to sell similar amounts of copper midcycle in 2029, though we expect gold volumes to decline to about 700,000 ounces then due to falling production at Grasberg.
In light of the recent options history for Freeport-McMoRan, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Freeport-McMoRan's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 6,060,712, the FCX's price is down by -4.08%, now at $37.37. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 60 days.</li>
</ul>
<h3>Expert Opinions on Freeport-McMoRan</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $45.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on Freeport-McMoRan, which currently sits at a price target of $45. 
&#x2A; An analyst from Jefferies downgraded its action to Hold with a price target of $40. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Freeport-McMoRan, which currently sits at a price target of $50. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Freeport-McMoRan with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Looking At Freeport-McMoRan's Recent Unusual Options Activity

Elon Musk doesn't just work hard—he sleeps hard. The billionaire tech mogul has reportedly been crashing on the floor of his government office, which sits just across from the West Wing of the White House.
Since taking on his new role as head of the Department of Government Efficiency under President Donald Trump, Musk has been spending long hours at the Eisenhower Executive Office Building—so long that he's apparently decided to just sleep there.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
<h2 class="wp-block-heading">Sleeping In The Office—Again</h2>
A Republican source told People that Musk has been &#8220;holed up&#8221; in his government office, sometimes sleeping on the couch and sometimes straight-up on the floor. Not exactly Tesla's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp; luxury interiors, but Musk has never been big on comfort.
It's not the first time Musk has made an office his bedroom. He famously <a href="https://www.youtube.com/watch?v=fTj3h7wp1Mw">lived in a Tesla factory </a>for three years, sleeping on a couch, under his desk, and even in a tent on the roof. His reasoning back then? Too much work, not enough time to go home.
Now, history seems to be repeating itself—only this time, instead of a Tesla plant, his makeshift bedroom is in a government building next to Trump's White House.
Trending: Many don&#8217;t know there are tax benefits when buying a unit as an investment —<a href="https://www.benzinga.com/money/casa-shares"> Here&#8217;s how to invest in real estate by mirroring BlackRock's big move</a>
<h2 class="wp-block-heading">Government Office? More Like A Full-Time Home</h2>
The EEOB, where Musk has been sleeping, houses various agencies under the Executive Office of the President. It's next to the White House, making it easy for Musk to stay close to Trump.
And while Musk may not have a bed, the EEOB does have perks. A cafeteria, a gym, and even a bowling alley are available for government employees, so at least he's not starving.
But Musk isn't the only one spending extra time in the office. His 4-year-old son, X Æ A-Xii, has reportedly been around "quite a bit." The toddler even made an appearance at a <a href="https://www.youtube.com/watch?v=zqjjPYekxgM&amp;ab_channel=FOX9Minneapolis-St.Paul">Feb. 11 Oval Office press conference,</a> standing beside Musk and Trump while making faces at reporters.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
<h2 class="wp-block-heading">Mar-a-Lago: Musk's Other "Home"</h2>
When Musk isn't sleeping in his government office, he's reportedly spending time at Mar-a-Lago. <a href="https://people.com/elon-musk-sleeping-office-floor-near-white-house-exclusive-11678717">People magazine quoted sources</a> as saying he was living at Trump's Florida resort during the presidential transition, helping shape the administration's tech policies.
One Palm Beach told People last month that Melania Trump was "glad to have a babysitter for Donald" while Musk was hanging around.
<h2 class="wp-block-heading">So, Why Is Musk Sleeping There?</h2>
It's unclear exactly why Musk is choosing to sleep in the EEOB, but given his history, it's likely just about efficiency. If you ask Musk, he'd probably say something like &#8220;too much work, no time to leave.&#8221;
The White House has not commented on his sleeping habits. Neither has Musk. But for now, the world's richest man is apparently sleeping on the floor, just a few steps from Trump's White House.
Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

TSLA

Elon Musk's New Crash Pad? The Floor Of His Government Office Next To Trump's West Wing

Bybit founder Ben Zhou has raised concerns that multisig wallet provider Safe may have been compromised, allowing <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43886224/bybit-founder-confirms-1-4-billion-ethereum-hack-blames-masked-transaction">hackers to steal $1.4 billion</a> in Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). 
Speaking in a live stream, Zhou explained that the attack targeted Bybit's Ethereum cold wallet, but all other wallets, including its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reserves, remain unaffected.
<h3 class="wp-block-heading">How The Attack Unfolded</h3>
Zhou recounted how the attackers manipulated Bybit's signing process while maintaining the appearance of a legitimate Safe transaction.
&#8220;It was a normal URL. I double-checked. It was the Safe URL from the official Safe website. We always use the official website,&#8221; Zhou said.
He explained that as part of standard security measures, he verified the UI and destination address, ensuring it matched Bybit's warm wallet before approving the transfer. 
However, the actual signing message was altered, not to authorize a simple transfer, but instead to modify the smart contract logic of the cold wallet.
&#8220;The hacker changed that transaction into upgrading or changing the Safe smart contract logic so that he gained control over the entire Ethereum cold wallet,&#8221; Zhou revealed.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43883117/coinbase-ceo-brian-armstrong-says-sec-has-agreed-to-end-bogus-enforcement-case-without-penalties">Coinbase CEO Brian Armstrong Says SEC Has Agreed To End &#8216;Bogus&#8217; Enforcement Case Without Penalties</a>
<h3 class="wp-block-heading">Extent of the Damage And Bybit's Response</h3>
The total stolen amount includes:
<ul>
<li>401,347 ETH ($1.12 billion)</li>
<li>90,376 stETH ($253 million)</li>
<li>15,000 cmETH ($44 million)</li>
<li>8,000 mETH ($23 million)</li>
</ul>
Despite the breach, Zhou assured users that withdrawals remain open, although processing times have increased due to a surge in requests. 
At the peak, Bybit was handling nearly 100 times the normal withdrawal volume. 
The exchange is currently relying on a bridge loan from partners to maintain liquidity while resolving the issue.
&#8220;We are not currently buying ETH. We secured almost 80% of the stolen amount as a bridge loan to maintain liquidity,&#8221; Zhou confirmed.
<h3 class="wp-block-heading">Investigating The Breach</h3>
Bybit is working closely with Safe's team to determine whether the attack stemmed from a vulnerability on Safe's end. 
Zhou stated that Safe has paused its services to conduct further internal investigations.
&#8220;It could be that the Safe server was hacked, but we don't know yet. We are actively working with Safe to uncover what happened,&#8221; Zhou said.
<h3 class="wp-block-heading">Tracking The Stolen Funds</h3>
Bybit has also received support from major exchanges such as Binance and MEXC and Gate which have pledged to help track and block the stolen assets. 
Zhou encouraged security firms and blockchain analysts to assist in monitoring the movement of funds in hopes of freezing the stolen Ethereum before it is laundered.
<h3 class="wp-block-heading">What's Next?</h3>
Bybit confirmed that it has the financial reserves to cover client losses, stating that the stolen Ethereum represents only a fraction of the exchange's total assets. 
The company also reiterated its commitment to security enhancements and will continue updating users as the investigation progresses.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43879013/after-im-a-nazi-rant-on-x-kanye-west-is-reportedly-considering-a-token-after-all">After &#8216;I&#8217;m A Nazi&#8217; Rant On X, Kanye West Is Reportedly Considering A Token After All</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Bybit Founder Says $1.4B ETH Hack May Stem From Safe Wallet Compromise

HC Wainwright &amp; Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and maintains $74 price target.

Reiteration

SWTX

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

Press Releases

10x Genomics Reports Third Quarter 2024 Financial Results

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

BRKR

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

10x Genomics

ニュース

最新ニュース 10x Genomics (NASDAQ:TXG) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル